An initiative of the Open Source Medicine Foundation — opensourcemed.info

Open Source Medicine Foundation

Vaccine Data Navigator

Compiled August 2026

The only place that puts VAERS, Canada Vigilance, JADER, and EudraVigilance side by side — plus routine immunization schedules for 37 countries, drawn straight from primary sources.

No other public tool lets you compare adverse-event reporting across national pharmacovigilance systems for the same vaccine, or see how a country's schedule differs from the next one over. This does both, sourced from FDA review documents, national surveillance databases, and peer-reviewed literature — not aggregator summaries.

Database counts are unverified reports, not proven injury rates. Not medical advice.

Lead feature

Global Schedule Matrix

Routine childhood, adolescent, and travel schedules for 37 countries, side by side.

Open Schedule Matrix →

Cross-system comparison

Pharmacovigilance Comparison

VAERS, Canada Vigilance, JADER, and EudraVigilance for the same vaccine, in one table. Only VAERS publishes lot-level data — here's what the others show instead.

Compare Systems →

Vaccine Side Effects Index

Browse adverse event data by vaccine, with VAERS and international pharmacovigilance mirrors.

Browse Side Effects

Vaccine Lot & Batch Lookup

Search VAERS reports by lot number, with volume and seriousness context.

Search by Lot How to Search VAERS
ⓘ About These Pages

Each vaccine page follows a consistent evidence structure:

  • Basic Information
  • Pre-Licensure Clinical Trial Data
  • Post-Licensure Safety Data
  • Documented Adverse Events (with evidence strength ratings)
  • Disease Prevention Benefits
  • Evidence Summary
  • Key References
  • International Surveillance & Global Data
  • Curated Adverse Event Literature (case reports & series)

Data are drawn from:

  • FDA review documents
  • Published clinical trials
  • Vaccine Safety Datalink (VSD) analyses
  • VAERS summaries
  • Institute of Medicine / National Academies consensus reports
  • Cochrane systematic reviews
  • Peer-reviewed literature

Safety and efficacy data are presented without interpretive language that implies a vaccine is "safe" or "unsafe." Where findings are inconsistent or limited, those limitations are explicitly stated.

The country schedule selector below reflects a simplified, representative view of each nation's routine universal recommendations as of mid-2026 and is not a substitute for the live national schedule — immunization policy changes frequently (the U.S. schedule itself is currently subject to active litigation). Always verify against your national health authority.

Infant · Child

MMR

Measles, Mumps & Rubella

Live attenuated vaccine. Two-dose series at 12–15 months and 4–6 years. Covers M-M-R® II and PRIORIX.
Birth · Infant

Hepatitis B

HepB — 3-dose series starting at birth

Recombinant vaccine. Covers Engerix-B®, Recombivax HB®, Heplisav-B®, and PreHevbrio®.
Adolescent

HPV

Human Papillomavirus — 2 or 3 doses ages 9+

Virus-like particle vaccine. Covers Gardasil® 9 (9-valent) and historical products. First anti-cancer vaccine.
Infant · Child · Adult

DTaP / Tdap

Diphtheria, Tetanus & Pertussis

5-dose infant DTaP series + adolescent Tdap booster. Maternal Tdap during pregnancy.
Infant

Hib

Haemophilus influenzae type b

Conjugate vaccine. 2–3 dose primary series + booster. >99% reduction in invasive Hib disease.
Infant · Child

Polio (IPV)

Inactivated Poliovirus Vaccine

4-dose series. U.S. switched from OPV to IPV in 2000 to eliminate vaccine-associated paralytic polio risk.
Infant

PCV (Pneumococcal)

Pneumococcal Conjugate — PCV13/15/20

4-dose series. PCV7 pivotal trial (N=38,000) was one of the largest pediatric vaccine trials.
Infant (oral)

Rotavirus

Live attenuated oral vaccine

2–3 dose series. Pivotal trials among the largest ever (~130,000 infants). Small intussusception risk identified post-licensure.
Infant · Child

Varicella

Chickenpox — 2-dose series

Live attenuated vaccine. Standalone (Varivax®) or MMRV combination (ProQuad®). MMRV has elevated febrile seizure risk vs. separate administration.
Infant · Child

Hepatitis A

HepA — 2-dose series starting at 12 months

Inactivated whole-virus vaccine. One of the least reactogenic vaccines on the pediatric schedule.
Adolescent

Meningococcal

MenACWY & MenB — Adolescent

MenACWY (2 doses, universal) + MenB (shared decision-making). Licensed via immunogenicity, not clinical efficacy.
Annual · All ages

Influenza

Seasonal Flu — Annual vaccination

Reformulated annually. IIV (injection) and LAIV (intranasal). Variable effectiveness (10–60%). 1976 GBS signal historical context.
Updated · All ages

COVID-19

SARS-CoV-2 — mRNA & protein subunit

Largest safety database in history (675M+ U.S. doses). Myocarditis signal in adolescent males. Updated formulations for variants.
Adult · ≥50

Shingles (Shingrix)

Zoster — 2-dose recombinant

Trial reactogenicity + VAERS lot data. High search volume anchor spoke.
Infant · Maternal · Adult

RSV

Arexvy, Abrysvo, Beyfortus

2023–2024 preventives — VAERS lots and pivotal trial safety tables.

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation

Home of the OSMF network — open-source pharmacovigilance tools and evidence-based medicine resources.

Research Tracker

Track peer-reviewed literature on vaccine safety, pharmacovigilance, and post-market surveillance.

SpikeProtein.site

Comprehensive resource on spike protein biology, biodistribution, and clinical implications.

VitalScan4PACVS

Decentralized trial for PACVS (post-acute COVID-19 vaccination syndrome).

PACVS Research Summit

Annual summit convening researchers and clinicians studying post-acute COVID-19 vaccination syndrome.